Around 480,000 people in England have chronic primary open angle glaucoma (POAG) (Moorfields, 2019). Estimates of population prevalence for ocular hypertension (OHT) range from 4.5% to 9.4% for those over 40 years old (Burr et al, 2012), and 10% of those with untreated OHT will develop POAG within five years (COptom, 2018).
The Royal College of Ophthalmologists predicts that, between 2015 and 2035, glaucoma cases will rise by 44% (RCOphth, 2017).
In 2009, NICE recommended that prostaglandin analogues (PGAs) should be the first choice of treatment for patients with glaucoma. NICE also recommended PGAs be used for patients with treatable OHT if their corneas were less than 555μm thick. Beta blockers were recommended for use in treatable OHT if the patient’s corneas were 555 to 590μm thick, providing they were not contraindicated – in which case a PGA should be used.
However, with the arrival of cost-effective generic PGAs, NICE changed its guidance in 2017 to recommend treatment with PGAs for patients with OHT who have intraocular pressure of 24mmHg or above, if they are at risk of visual impairment within their lifetime. Although corneal thickness is no longer mentioned specifically, it will be taken into account by the prescriber in determining whether the patient is at risk of visual impairment.
But beta blockers are not fading into insignificance. Daniel Hardiman-McCartney FCOptom, Clinical Adviser for the College, says: “Recent prescribing data shows that around 33% of items prescribed by GP practices for the treatment of glaucoma in England contain a beta blocker [Open Prescribing, 2019]. Although the use of stand-alone beta blockers is decreasing, a notable number of people will continue to be prescribed them as a combination therapy for the foreseeable future.”
Optometrists should be able to identify the side effects of both PGAs and beta blockers as part of active care for their patients (see Side effects).